A randomized controlled trial comparing the first-line eradication rate using vonoprazan or PPI for Helicobacter pylori infectious gastritis.

A randomized controlled trial comparing the first-line eradication rate using vonoprazan or PPI for Helicobacter pylori infectious gastritis. - A randomized controlled trial comparing the first-line eradication rate using vonoprazan or PPI for Helicobacter pylori infectious gastritis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021148

Enrollment

200

Registered

2016-02-23

Start date

2016-02-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infectious gastritis.

Interventions

We give vonoprazan 20mg and amoxicillin 750mg and clarithromycin 200mg or 400mg twice daily for 7 days. We give rabeprazole 20mg and amoxicillin 750mg and clarithromycin 200mg or 400mg of the pack pre

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: H.pylori infectious gastritis.

Exclusion criteria

Exclusion criteria: 80 years old or older. A patient has severe organ dysfunction. A patient having allergy of the study drug. A patient that it was judged that eradication was inappropriate on the medical examination of the medical attendant.

Design outcomes

Primary

Measure	Time frame
Eradication rates and adverse events. We evaluate the eradication in all cases using C13-urea breath test (UBT) at eight weeks after completion of the therapy. We perform a questionnaire to a patient, and we evaluate presence of a diarrhea, loose stool, exanthem, taste disorder, fever, other physical condition defectiveness about the side effect.	—

Secondary

Measure	Time frame
Taking medicine compliance.	—

Countries

Japan

Contacts

Public Contactmasafumi maruyama

nagano red cross hospital gastroenterology

m.maruyama@nagano-med.jrc.or.jp026-226-4131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026